CLDX - Celldex Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908-200-7500
http://www.celldex.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees192

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony S. MarucciFounder, Pres, CEO & Director873.75kN/A1962
Dr. Tibor Keler Ph.D.Founder, Chief Scientific Officer and Exec. VP552.71kN/A1959
Ms. Elizabeth CrowleyChief Product Devel. Officer and Sr. VP423.2kN/A1972
Mr. Sam MartinSr. VP, CFO, Principal Accounting Officer & TreasurerN/AN/AN/A
Ms. Sarah CavanaughSr. VP of Corp. Affairs & Admin.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 3. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.